Category Archives: Other

Icosema Launches in China; Medicare GLP-1 Bridge Reaches 100k Patients; Ex-Lilly Exec Joins Zealand; July CHMP Agenda

A series of cardiometabolic-related news items has been observed by Fangzhou/Novo Nordisk, CMS, Zealand Pharma, and EMA. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Merck’s Oral PCSK9i Approved by FDA; BI Ph2 Triple Agonist Study; Abbott Q2 ’26 Earnings; Syntis Ph1 Obesity Data; Lilly Invests in Oura; Braveheart IPO

A series of cardiometabolic-related news items has been observed from Merck, Boehringer Ingelheim, Abbott, Syntis Bio, Oura/Lilly, and Braveheart. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo’s Wegovy Pill Receives Approval in EU; Gubra Initiates FIH Study for Muscle-Sparing Asset; GSK Initiates Ph3 Efimosfermin Studies in MASH; Fractyl One Year Data; Ascletis Selects Another FDC in Obesity; Rani Topline Ph1 Data; BI H1 2026 Updates

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Gubra, GSK, Fractyl Health, Ascletis Pharma, Rani Therapeutics, and Boehringer Ingelheim. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

D&D and Pfizer Expand Research Agreement; Dexcom G7 15-Day Health Canada Clearance; Insulet Partners with Calm

Three cardiometabolic-related news items have been observed: D&D Pharmatech extended its oral obesity research agreement with Pfizer (view article), Dexcom received clearance of its G7 15-Day CGM in Canada (view press release), and Insulet partnered with Calm to provide well-being resources for diabetes management (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Zverev Sports MiniMed at Wimbledon; CSPC/AZ Milestone Payment; Madrigal Rezdiffra Patents; Novo AMAZE 3 Zenagamtide Study

A series of cardiometabolic-related news items has been observed from MiniMed, CSPC Pharmaceutical, Madrigal Pharmaceuticals, and Novo Nordisk. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Novo Initiates NLPR3i Obesity Study; Rani Partners with China-based Biotech Drug Delivery; Pfizer Gets New Head of Obesity Discovery; Novo Sponsors Athletes at Wimbledon

A series of cardiometabolic-related news items has been observed from Novo Nordisk, Rani Therapeutics/PegBio, and Pfizer. Below, FENIX provides highlights and insight for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Hengrui Ph2 Triple Agonist Study; MindRank Series B; Semaglutide on NEDL; New Foundayo DTC Ad; Endogenex ReCET Enrollment Complete; Ionis/AZ Miss Primary Endpoint in CARDIO-TTRansform; Dr. Reddy’s Halts Sema

A series of cardiometabolic-related news items has been observed by Hengrui, MindRank, Lilly, Endogenex, Ionis/AstraZeneca, and Dr. Reddy’s. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Kalohexis Files for US IPO

Kalohexis announced it has submitted a draft S-1 registration statement to the SEC ahead of its planned US IPO. The biotech, spun out of Endevica Bio in March 2026, is developing melanocortin-3 and -4 receptor (MC3R/MC4R) therapies for metabolic disorders, including obesity and cachexia in patients with advanced cancers (view website). Below, FENIX provides highlights and insights regarding Kalohexis’s IPO.

This content is for Read Less members only.

Already a member? Log in here

Vivani + Novo Partner for Sema Implant; Kailera Ph3 Oral Obesity and T2DM Data; TIXiMED Ph1b MAD Study; ESC 2026 Hot Line Sessions

A series of cardiometabolic-related news items has been observed from Vivani Medical/Novo Nordisk, Kailera Therapeutics, TIXiMED, and European Society of Cardiology. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

AZ/CSPC CVRM Deal; Amgen Initiates New Ph1 T2DM Study; Ascletis Files US INDs; Regeneron Posts New Ph2 Olatorepatide Study; Trinity CGM+ Results; Wegovy MASH MHRA Approval; Adocia/Sanofi M1Pram Agreement Expiration; ViCentra Hybrid Closed Loop Germany Launch

A series of cardiometabolic-related news items has been observed from AstraZeneca/CSPC Pharmaceutical, Amgen, Ascletis Pharma, Regeneron Pharmaceuticals, Trinity Biotech, MHRA, Adocia, and ViCentra. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here